Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16979247 | 1.00 | SLC6A9 (0.35) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL16979208 | 0.93 | SLC6A9 (0.33) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL16979235 | 0.92 | SLC6A9 (0.34) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL16979231 | 0.90 | CHRM1 (0.36) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL13289850 | 0.89 | SLC6A9 (0.35) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL16979172 | 0.89 | SLC6A9 (0.35) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL16979229 | 0.88 | SLC6A9 (0.32) | SLC6A9PDE4B | |
| SCHEMBL16979230 | 0.88 | CHRM1 (0.35) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL16983558 | 0.87 | SLC6A9 (0.34) | SLC6A9PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL16983260 | 0.87 | SLC6A9 (0.34) | SLC6A9PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783481-B2 | Carbonyl derivative, liquid crystal composition containing compound thereof and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | RCC2, RCC1, ROCK2 | SLC6A9 4280/4885PDE4B 2577/4885PDE4D 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.